Call for Abstract

12th International Conference on Chronic Obstructive Pulmonary Disease Conference, will be organized around the theme “”

COPD 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in COPD 2020

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

COPD is a group of progressive lung diseases. The common are emphysema and chronic bronchitis. Many people with COPD have both of these conditions. Emphysema slowly destroys air sacs in lungs, which affects with external air flow. Bronchitis causes inflammation and narrowing of the bronchial tubes, which permits mucus to form. It also includes asthma and certain forms of bronchiectasis. COPD makes it harder to breathe. Indications may be mild at initial stage with cough and shortness of breath. As it progresses, it can become increasingly difficult to breathe. COPD Conferences focus on the modern approaches of Pulmonology.

  • Track 1-1Pulmonology
  • Track 1-2Bronchiectasis
  • Track 1-3Obstructive lung disease
  • Track 1-4Pulmonary Emphysema
  • Track 1-5End-stage Lung Disease

Inflammation is present in the lungs, especially the small airway routes, of all people who smoke. COPD Pathogenesis is typical defensive reaction to the inhaled toxins is enhanced in COPD, leading to tissue destruction, debilitation of the defence mechanisms and interruption of the repair mechanisms. In general, the inflammatory and structural changes in the airway routes increased with disease seriousness and hold on even after smoking cessation. Other than inflammation, two different procedures are associated with the pathogenesis of COPD—an irregularity amongst proteases and antiproteases and an imbalance amongst oxidants and antioxidants agents in the lungs. Pulmonary Conferences expresses various developing treatments for COPD.

  • Track 2-1Airway inflammation
  • Track 2-2Mucociliary dysfunction
  • Track 2-3Protease imbalance
  • Track 2-4Antiprotease imbalance

Bronchial Asthma and Chronic Obstructive Pulmonary Disease are obstructive pneumonic sicknesses that influenced a large number of people everywhere throughout the world. Chronic Obstructive Pulmonary Disease (COPD) is a group of pulmonary diseases that block air stream in the lungs. Asthma is a chronic disease noticeable by spasms of bronchi, due to inflamed and narrowed airways in the lungs. Asthma causes difficulty in breathing that often results from an allergic reaction. There is large evidence that treatment with anti-inflammatory drugs reduces morbidity and mortality in asthma. Inhaled corticosteroids appear to have a place in the management of severe chronic obstructive pulmonary disease, perhaps by decreasing the frequency of exacerbations. Lung Conferences envelop the fields of asthma and COPD which have important similarities and differences. Asthma and COPD are chronic inflammatory diseases that include the little airway routes and cause airflow impediment, both result from gene environment communications and both are typically characterized by mucus and bronchoconstriction.

  • Track 3-1Airflow obstruction
  • Track 3-2Bronchospasm
  • Track 3-3Nocturnal Asthma
  • Track 3-4Chronic Obstructive Airways Disease

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease in responsible for human and economic burden around the world. Cigarette smoking is the fundamental hazard factor for COPD in the developed world, although other essential respiratory disorder incorporate word related exposures, air contamination, airway route hyper responsiveness, asthma, and hereditary predisposition. In the vast majority of the world, Epidemiology of COPD prevalence and mortality keep on rising in light of increases in smoking addiction, especially by women and adolescents. COPD is likewise an imperative reason for disability, and is connected to comorbid diseases, for example, depression and cardiovascular disease, which adds to the large economic burden related with this issue. Better public health and medical intercessions that target both the risk factors for COPD and look toward prior mediation may decrease growing public health impact of COPD. COPD Conferences will focus on the understanding of all the pulmonary treatments.

  • Track 4-1Morbidity of COPD
  • Track 4-2Molecular and Genetic Risk Factors
  • Track 4-3Occupational Exposure
  • Track 4-4Mortality of COPD
  • Track 4-5Social and economic factors

The objective of COPD therapeutics is to enhance a patient's functional status and quality by protecting optimal lung function, enhancing indications, and keeping the recurrence of COPD exacerbations. At present, no medicines aside from lung transplantation have been appeared to significantly enhance lung function or decrease mortality; however, oxygen therapy and smoking cessation may decrease mortality. Once the diagnosis of COPD is established, it is essential to educate the patient about the sickness and to empower their active interest in treatment. Bronchodilators are the foundation of any COPD treatment regimen. They work by enlarging aviation routes, accordingly diminishing airsac protection. Pulmonary Conferences provides a multidisciplinary to pulmonology researchers.

  • Track 5-1Smoking Cessation
  • Track 5-2Bronchodilators
  • Track 5-3Corticosteroids
  • Track 5-4Oxygen Therapy
  • Track 5-5Pulmonary Rehabilitation

Constant Obstructive Pulmonary Disease (COPD) experiences long-term and dynamic damage to their lungs. This impacts air flow to the lungs. Doctors in some cases call this condition chronic bronchitis or chronic emphysema. Those with COPD can experience periods when their signs are much worse than normal. This is known as an acute exacerbationShortness of breath and chest tightness is present in many cases. A patient encountering a COPD exacerbation may need to search for medicinal help at a hospital. COPD exacerbations can be harmful because they can make damage to the lungs. COPD, keeping a compounding from happening can enable you to live a healthier life and diminish risk of death. Self-management and prevention for COPD will be beneficial for future exacerbation. Lung Conferences will explore the application of pulmonology.

  • Track 6-1Acute Exacerbation
  • Track 6-2Pathophysiology of exacerbations
  • Track 6-3Management of Exacerbation

People with different types of COPD experience difficulty in breathing and shortness of breath. The two principle infections that fall under the extent of COPD are: Chronic bronchitis, which involves a long-term cough with mucus, it is a long-term inflammation of the bronchi, which results in increased production of mucus, as well as other changes. These changes may result in breathing problems, frequent infections, cough, disability, anxiety and depression. Emphysema, which involves damage to the lungs over time. Emphysema is a chronic lung condition in which alveoli may be: destroyed, narrowed, collapsed, stretched, and over-inflated. This can cause a reduction in respiratory capacity and breathlessness. Harm to the air sacs is irreversible and brings about permanent "holes" in the lung tissue. COPD Conferences will focus on the different techniques used in pulmonology.

  • Track 7-1Chronic Bronchitis
  • Track 7-2Emphysema
  • Track 7-3Pulmonary Emphysema
  • Track 7-4Obstructive lung disease

For Chronic Obstructive Pulmonary Disease there are no sign and symptoms or sometimes it may show mild symptoms. As the disease gets inferior, symptoms usually progress more severe. The first symptom of COPD is usually a long-term or chronic cough. If you have COPD, you also may often have colds or other respiratory infections such as the flu, or influenzaPulmonary Conferences discuss about the COPD symptoms, often don't appear until significant lung damage or lung cancer has occurred, and they usually worsen over time, particularly if smoking exposure continues. Symptoms include increasing breathlessness – this may just occur when exercising at first and you may sometimes wake up at night feeling breathless, a persistent chesty cough with phlegm that never seems to go away, frequent chest infections, persistent wheezing.

  • Track 8-1Shortness of breath
  • Track 8-2Wheezing
  • Track 8-3Chest tightness
  • Track 8-4Chronic Cough
  • Track 8-5Unintended weight loss
  • Track 8-6Alpha2-macroglobulin

Even if an individual has never smoked or been unprotected to pollutants for an extended period of time, they can still develop COPDAlpha-1 Antitrypsin Deficiency (AATD) is the most commonly known genetic risk factor of COPD in emphysema. Alpha-1 Antitrypsin related COPD is caused by a deficiency of the Alpha-1  in the bloodstream. Without the Alpha-1 Antitrypsin protein, white blood cells begin to harm the lungs and lung deterioration occurs. The World Health Organization and the American Thoracic Society suggests that each individual determined to have COPD be tested for Alpha-1Pulmonary Conferences also discusses about different types of genes which may be a cause of pulmonary diseases.

 

  • Track 9-1Alpha1-antitrypsin
  • Track 9-2Alpha1-antichymotrypsin
  • Track 9-3Cystic fibrosis transmembrane regulator
  • Track 9-4Vitamin D-binding protein

Patients with chronic obstructive pulmonary disease are at increased risk for both the development of primary lung cancer, as well as poor outcome after lung cancer diagnosis and treatment. Because of existing impairments in lung function, patients with COPD often do not meet traditional criteria for tolerance of definitive surgical lung cancer therapy. Emerging information with respect to the pathophysiology of COPD in lung resection demonstrates that postoperative decrements in lung capacity may be less than anticipated by traditional prediction tools. In patients with COPD, more inclusive consideration for surgical resection with curative intent might be appropriate as constrained surgical resections or nonsurgical therapeutic options provide inferior survival. Besides, optimizing perioperative COPD therapeutic care as indicated by clinical practice rules including smoking cessation can possibly minimize morbidity and enhance functional status in this often severely impaired patient population. Lung Conferences concentrates on the risk factor for development of lung cancer.

  • Track 10-1Small-Cell Lung Carcinoma
  • Track 10-2Prognosis of Lung Cancer
  • Track 10-3Genetic susceptibility
  • Track 10-4Chronic inflammation

Chronic obstructive pulmonary disease is related with increased risk of cardiovascular disease, for example, heart failure or a heart attack. The lungs and the heart work firmly together to supply the oxygen; oxygen in the air that comes into the lungs is moved into the circulation system, which the heart at that point pushes out to rest of the body. But diseases in both the heart and the lungs often go together. If person have COPD then there is a higher risk of having cardiovascular diseases. Comorbidities and chronic obstructive pulmonary disease (COPD) are pervasive, with cardiovascular disease being the most well-known and significant. Risk factors for COPD and Cardiovascular Diseases, such as smoking, low socioeconomic class, and a sedentary lifestyle contribute to the natural history of each of these conditions. COPD Conferences will focus on the scope of COPD related to cardiovascular diseases.

  • Track 11-1Pathogenesis
  • Track 11-2Vascular remodelling
  • Track 11-3Dynamic hyperinflation
  • Track 11-4Pulmonary artery catheterization
  • Track 11-5Respiratory Treatment and Dysrhythmias

Pulmonary hypertension is a type of high blood pressure that impacts the arteries in lungs and the right side of heart. In one type of pulmonary hypertension, modest arteries in lungs, called pulmonary arterioles, and capillaries become narrowed, blocked or destroyed. This makes it harder for blood to flow through lungs, and raises pressure inside the arteries of lungs. As the pressure builds, heart's lower right chamber (right ventricle) must work harder to direct blood through lungs, in the end causing heart muscle to debilitates and fail. Few categories of pulmonary hypertension are serious conditions that become progressively worse and sometimes become fatal. Pulmonary hypertension can lead to a number of COPD complications such as blood clots in the lungs, sickle cell disease and sleep apnea. Although a few kinds of pulmonary hypertension are not curable, treatment can help decrease symptoms and enhance quality of life. Pulmonary Conferences concentrates on the impact of pulmonary hypertension.

  • Track 12-1Pulmonary arterial hypertension
  • Track 12-2Pulmonary Embolism
  • Track 12-3Pulmonary Venous Hypertension
  • Track 12-4Molecular pathology

Chronic obstructive pulmonary disease (COPD) is a life-threatening condition. It affects lungs and ability to breathe. The pathophysiology of COPD is the physical changes associated with it, start with damage to airways and the air sacs in lungs. It progresses from a cough with mucus to difficulty breathing. To understand pathophysiology of COPD, it is essential to understand the structure of the lungs. When you inhale, air moves down in trachea through two tubes called bronchi. The bronchi branch out into smaller tubes called bronchioles. At the ends of the bronchioles are little air sacs called alveoli. And at the end of alveoli are capillaries, which are tiny blood vesselsLung Conferences envision the pulmonology.

  • Track 13-1Inflammatory mediators
  • Track 13-2Oxidative stress
  • Track 13-3Mucous Hypersecretion
  • Track 13-4Air trapping

Additional pulmonary comorbidities impact the anticipation of patients with COPD. Tobacco smoking is a typical hazard factor for much comorbidity, including coronary illness, heart failure and lung cancer. Comorbidities, for example, pulmonary artery disease and malnutrition are specifically caused by COPD, while others, such as fundamental venous thromboembolism, anxiety, depression, osteoporosis, obesity, metabolic disorder, diabetes, sleep disturbance and anaemia, have no clear physiopathological association with COPD. Co-Morbidities of COPD shared conviction between the majorities of these extra pulmonary signs is chronic systemic inflammation. These diseases potentiate the morbidity of COPD, prompting expanded hospitalisations and healthcare costs. They can frequently cause death, independently of respiratory failure. Comorbidities make the management of COPD difficult and should be evaluated and treated adequately. COPD Conferences enlighten the recent advances in COPD and pulmonology research.

  • Track 14-1Cardiac Disease
  • Track 14-2Diabetes Mellitus
  • Track 14-3Hypertension
  • Track 14-4Osteoporosis
  • Track 14-5Psychological Disorders

Individuals with COPD can be in risk for serious complications that can not only put their health in jeopardy, but can also be fatal. Cor Pulmonale of COPD bring down extremity edema (swelling) in a patient with COPD Complications is typically an indication of cor pulmonale (pulmonary hypertension and right-sided heart failure). Acute COPD Exacerbations are portrayed by an unexpected increment of manifestations. Cough and sputum production increases. At the point when respiratory failure happens in a patient who slowly, there is a moderate decrease in lung capacity and rising levels of carbon dioxide in the blood. The expanding carbon dioxide makes an opiate impact in the patient, who gradually loses awareness and quits relaxing. Different difficulties of COPD incorporate pneumonia, polycythemia, and pneumothorax. Pneumonia caused by bacterial disease can prompt respiratory failure in these patients. Streptococcus pneumoniae is the most well-known reason for bacterial pneumonia in patients with COPD. Pneumothorax happens when a hole develops in the lung, enabling air to escape into the space between the lung and the chest wall and collapsing the lung. Polycythemia in COPD is the body's endeavour to adjust to decreased amount of blood oxygen by expanding the generation of oxygen-conveying red blood cells. While this might be useful temporarily, overproduction eventually clogs small blood vessels. COPD Conferences provides global forum for discussion about new innovation of pulmonology research.

  • Track 15-1Acute Exacerbations
  • Track 15-2End-stage Lung Disease
  • Track 15-3Cor Pulmonale
  • Track 15-4Pneumothorax
  • Track 15-5Lung cancer

There's currently no cure for chronic obstructive pulmonary disease (COPD), yet pulmonary diseases treatment and therapies can help moderate the movement of the condition and control the side effects. Medicines include: quit smoking, inhalers and pharmaceuticals – to help make breathing easier, pulmonary rehabilitation – a specific program of exercise and education surgery or a lung transplant – although this is only an option for a very small number of people. Much of the treatment for COPD includes self-management and prevention of COPDOxygen therapy can improve quality of life and is the only COPD therapy proven to extend life. Surgery is an option for some people with some forms of severe emphysema who aren't helped sufficiently by medications alone. Surgical options include: Lung volume reduction surgery, Lung transplant and BullectomyCOPD Conferences will disclose the application of different treatments and therapies.

  • Track 16-1Quit Smoking and Avoid Lung Irritants
  • Track 16-2Oxygen Therapy
  • Track 16-3Surgery
  • Track 16-4Lung Transplant
  • Track 16-5Bullectomy
  • Track 16-6Bronchodilators

Much of the focus of pulmonary rehabilitation, research and pneumonic medication goes toward the youngest individuals from society-the newborns. For instance, the reason for pulmonary stenosis is because of improper pulmonary valve improvement in the initial two months of fetal development. It's congenital but treatable. With a sound pulmonary stenosis diagnosis the heart valve can be replaced or repaired and children can grow to lead normal healthy lives. Sleep apnea affects premature babies. A situation called apnea of prematurity exists when the child doesn’t breath for 20 seconds or more. It is a pulmonary disease that can be treated with ventilation machines and medications. COPD Conferences explains about pediatric pulmonary, critical care and sleep which includes Pediatric emergencies, Pneumonia, Respiratory failure, Pediatric in-patient and critical care, Sepsis and Head Trauma & Concussion.

  • Track 17-1Pediatric Pulmonary Medicine
  • Track 17-2Pediatric Allergy
  • Track 17-3Sleep apnea
  • Track 17-4Pediatric Pulmonary Hypertension

Depression and anxiety in COPD are regular in patients with chronic obstructive pulmonary disease (COPD), assessments of their pervasiveness differ significantly. These likely reflect the assortment of scales and strategies used to measure such symptoms. Patients with COPD with three or more comorbidities are more likely to be frequently hospitalized and may die prematurely compared to COPD patients without comorbidities.  An uplifted experience of dyspnoea is probably contributing component to anxiety. Feelings of depression may be precipitated by the loss and grief associated with the disability of COPD. Smoking has been associated with nicotine addiction, and the factors that contribute to smoking may also predispose to anxiety and depressive disorders. The cause of depression and anxiety symptoms are multifactorial and include behavioural, social and biological factorsLung Conferences exhibits randomized controlled trials show that activity exercise training and precisely chose pharmacological treatment are regularly effective in ameliorating anxiety and depression.

  • Track 18-1Prevalence in COPD
  • Track 18-2Classification and diagnostic criteria
  • Track 18-3Clinical features and impact
  • Track 18-4Screening and diagnosis
  • Track 18-5Risk factors
  • Track 18-6Mechanism of potential association with COPD

Chronic obstructive pulmonary disease is an increasing worldwide medical issue and cause of death. COPD predominantly influencing small airway routes and lung parenchyma that prompts dynamic aviation route deterrent. COPD is a standout amongst the most widely recognized infections on the globe, and there is a global increase in prevalence, however there are no drugs available at present that halt the relentless progression of this disease. In any case, a superior comprehension of the cell and molecular mechanisms that are associated with the underlying inflammatory and destructive processes has uncovered a few new focuses for which drugs are presently being developed, and the prospects for finding new medications are good.

Self-Management and Prevention of COPD interventions help patients with chronic obstructive pulmonary disease (COPD) acquire and practise the skills they need to carry out disease-specific medical regimens, guide changes in health behaviour and provide emotional support to enable patients to control their disease. Patients with COPD confirmed by spirometry and symptoms and airflow obstruction should be monitored regularly to guide modification of treatment and to identify complications early Pulmonary Conferences will be focused on the self-management support programmes should be collaborative between healthcare professionals and patients, to help them acquire skills to understand and manage their medications and exacerbations of COPD, adopt healthier behaviours and manage the social-emotional consequences of the disease.

  • Track 20-1Health Care Utilization
  • Track 20-2Managing medication
  • Track 20-3Adjusting Lifestyle
  • Track 20-4Managing symptoms

Chronic obstructive pulmonary disease is one of the leading causes of disability and death worldwide. COPD exacerbation is usually treated with antibiotics, systemic corticosteroids, and inhaled bronchodilators. COPD exacerbation was treated repeatedly with standard therapy. Dynamic expiratory computed tomography of the chest was done, which revealed concomitant tracheomalacia. COPD and tracheomalacia may coexist during recurrent exacerbations of COPD, and delayed diagnosis can be associated with severe comorbidities. Ordering the appropriate imaging technique may aid in the correct diagnosis and facilitate appropriate management. COPD Conferences will survey the evolution of pulmonology.

  • Track 21-1Physical Examination
  • Track 21-2Diagnostic Studies
  • Track 21-3Environmental hazards